{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:03:43Z","timestamp":1760295823549},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["ACAMC"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:sec>\n<jats:title \/>\n<jats:p>Background: Ruthenium-based anti-cancer compounds are proposed as viable alternatives that might\ncircumvent the disadvantages of platinum-based drugs, the only metallodrugs in clinical use for chemotherapy.\nOrganometallic complexes in particular hold great potential as alternative therapeutic agents since their cytotoxicity\ninvolves different modes of action and present reduced toxicity profiles.\n&lt;\/p&gt;\n&lt;p&gt;\nObjective: During the last few years our research group has been reporting on a series of organometallic ruthenium(II)-\ncyclopentadienyl complexes with important cytotoxicity against several cancer cell lines, surpassing cisplatin in\nactivity. We report herein preliminary in vivo studies with one representative compound of this family, with\nexceptional activity against several human cancer cell lines, including the glycolytic and highly metastatic\nMDAMB231 cell line used in this study. \n&lt;\/p&gt;\n&lt;p&gt;\nMethod: The anti-tumor activity of our compound was studied in vivo on N:NIH(S)II-nu\/nu nude female mice bearing\ntriple negative breast cancer (TNBC) orthotopic tumors. Administration of 2.5 mg\/kg\/day during ten days caused cell\ndeath mostly by necrosis (in vitro and in vivo), inducing tumor growth suppression of about 50% in treated animals\nwhen compared to controls.\n&lt;\/p&gt;\n&lt;p&gt;\nResults: The most remarkable result supporting the effectiveness and potential of this drug was the absence of\nmetastases in the main organs of treated animals, while metastases were present in the lungs of all control mice, as\nrevealed by histopathological and immunohistochemical analysis.\n&lt;\/p&gt;\n&lt;p&gt;\nConclusion: These in vivo studies suggest a dual effect for our drug not only by suppressing growth at the primary\ntumor tissue but also by inhibiting its metastatic behavior. Altogether, these results represent a benchmark and a solid\nstarting point for future studies.\n&lt;\/p&gt;\n&lt;p&gt;<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871520616666160922165133","type":"journal-article","created":{"date-parts":[[2016,9,28]],"date-time":"2016-09-28T05:27:43Z","timestamp":1475040463000},"page":"126-136","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["In Vivo Performance of a Ruthenium-cyclopentadienyl Compound in an Orthotopic Triple Negative Breast Cancer Model"],"prefix":"10.2174","volume":"17","author":[{"given":"Nuno","family":"Mendes","sequence":"first","affiliation":[]},{"given":"Francisco","family":"Tortosa","sequence":"additional","affiliation":[]},{"given":"Andreia","family":"Valente","sequence":"additional","affiliation":[]},{"given":"Fernanda","family":"Marques","sequence":"additional","affiliation":[]},{"given":"Ant\u00f3nio","family":"Matos","sequence":"additional","affiliation":[]},{"given":"T\u00e2nia S.","family":"Morais","sequence":"additional","affiliation":[]},{"given":"Ana Isabel","family":"Tomaz","sequence":"additional","affiliation":[]},{"given":"F\u00e1tima","family":"G\u00e4rtner","sequence":"additional","affiliation":[]},{"given":"M. Helena","family":"Garcia","sequence":"additional","affiliation":[{"name":"Centro de Qu\u00edmica Estrutural, Faculdade de Ci\u00eancias da Universidade de Lisboa, Campo Grande, 1749- 016 Lisboa, Portugal.,Portugal"}]}],"member":"965","container-title":["Anti-Cancer Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871520616666160922165133","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/145730\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871520616666160922165133","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T11:31:14Z","timestamp":1657279874000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/145730\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871520616666160922165133","relation":{},"ISSN":["1871-5206"],"issn-type":[{"value":"1871-5206","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2016-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-07-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-09-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-12-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}